(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Fred Saad presented a secondary analysis of the change in patient reported pain among patients treated with rucaparib for metastatic castration resistant prostate cancer (mCRPC) in the TALAPRO-1 trial (NCT03148795). This trial enrolled men with progressive mCRPC and an 11-gene panel assessing tumor DNA Damage Response Alterations (DDRm) involved either directly or indirectly in homologous recombination repair (HRR). In the context of the trial, included men had received 1–2 taxane-based chemotherapy and progressed on ≥1 novel hormonal therapy before inclusion. The primary study endpoint was objective response rate ([ORR] per RECIST v.1.1; central review).